Abstract
Erythropoietin (EPO) has long been recognized as the major hematopoietic cytokine regulating normal erythropoiesis. Moreover, there is a growing interest in the non-erythropoietic, tissue-protective effects of EPO. Because of its potential to correct anemia, EPO has been increasingly prescribed to cancer patients. However, although recombinant human Epo (rHuEPO) significantly reduces the risk for red blood cell transfusions in cancer patients, recent clinical studies have reported decreased survival and disease control following rHuEPO treatment in patients with different cancer types. The issue of EPOR expression in tumor cells is critical in this respect. The expression of EPOR in tumor cells raises the possibility that exogenous rHuEPO may directly influence tumor growth or sensitivity to chemo-radiation therapy. In addition, EPOR expression in endothelial cells suggests what potential effects EPO may have on tumor capillaries, such as the stimulation of angiogenesis. However, as experimental studies reveal, the overall direct effect of EPO-EPOR signaling on cancer progression and therapy is not a straightforward one. The current paper provides an update on the biology of EPO, and discusses its utility in the treatment of cancer patients.
Keywords: Erythropoietin, hypoxia, anemia, cancer
Current Molecular Medicine
Title: Erythropoietin in Cancer: An Update
Volume: 8 Issue: 6
Author(s): Jozsef Tovari, Robert Pirker, Jozsef Timar, Gyula Ostoros, Gabor Kovacs and Balazs Dome
Affiliation:
Keywords: Erythropoietin, hypoxia, anemia, cancer
Abstract: Erythropoietin (EPO) has long been recognized as the major hematopoietic cytokine regulating normal erythropoiesis. Moreover, there is a growing interest in the non-erythropoietic, tissue-protective effects of EPO. Because of its potential to correct anemia, EPO has been increasingly prescribed to cancer patients. However, although recombinant human Epo (rHuEPO) significantly reduces the risk for red blood cell transfusions in cancer patients, recent clinical studies have reported decreased survival and disease control following rHuEPO treatment in patients with different cancer types. The issue of EPOR expression in tumor cells is critical in this respect. The expression of EPOR in tumor cells raises the possibility that exogenous rHuEPO may directly influence tumor growth or sensitivity to chemo-radiation therapy. In addition, EPOR expression in endothelial cells suggests what potential effects EPO may have on tumor capillaries, such as the stimulation of angiogenesis. However, as experimental studies reveal, the overall direct effect of EPO-EPOR signaling on cancer progression and therapy is not a straightforward one. The current paper provides an update on the biology of EPO, and discusses its utility in the treatment of cancer patients.
Export Options
About this article
Cite this article as:
Tovari Jozsef, Pirker Robert, Timar Jozsef, Ostoros Gyula, Kovacs Gabor and Dome Balazs, Erythropoietin in Cancer: An Update, Current Molecular Medicine 2008; 8 (6) . https://dx.doi.org/10.2174/156652408785747979
DOI https://dx.doi.org/10.2174/156652408785747979 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bioactive Compounds of <i>Polygonatum sibiricum</i> - Therapeutic Effect and
Biological Activity
Endocrine, Metabolic & Immune Disorders - Drug Targets Electrical Impedance Scanning - A New Diagnostic Tool in Cancer Detection: Current Status and Recent Developments
Current Medical Imaging The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Current Topics in Medicinal Chemistry p16<sup>INK4</sup> as a Biomarker in Oropharyngeal Squamous Cell Carcinoma
Recent Patents on Biomarkers Polo-Like Kinases (Plks) are Prognostic Markers for Gynecologic Malignancies
Current Women`s Health Reviews Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers Anticancer Potential and Molecular Targets of Pristimerin: A Mini- Review
Current Cancer Drug Targets Morphological Characterization of Lipid Structured Nanoparticles by Atomic Force Microscopy while Minimizing the Formation of Failed Artefacts
Current Nanomaterials Mitochondrial Permeability Transition as Target of Anticancer Drugs
Current Pharmaceutical Design Overview of the Metallometabolomic Methodology for Metal-Based Drug Metabolism
Current Drug Metabolism Detection of Tumor Markers with ProteinChip® Technology
Current Pharmaceutical Biotechnology The Origin and Identification of Mesenchymal Stem Cells in Teeth: from Odontogenic to Non-odontogenic
Current Stem Cell Research & Therapy Electroporation: An Effective Method For <i>In Vivo</i> Gene Delivery
Drug Delivery Letters The Roles of miR-25 and its Targeted Genes in Development of Human Cancer
MicroRNA Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Recent Advances in PUVA Photochemotherapy and PDT for the Treatment of Cancer
Current Pharmaceutical Design Cargo-Delivery Platforms for Targeted Delivery of Inhibitor Cargos Against Botulism
Current Topics in Medicinal Chemistry Function of miRNA in Controlling Drug Resistance of Human Cancers
Current Drug Targets